Tobacco use (F= former use, C= current use, N=never used) Primary diagnosis (3=
ID: 3200064 • Letter: T
Question
Tobacco use (F= former use, C= current use, N=never used)Primary diagnosis (3= irritable towel syndrome, 4= psoriatic arthritis, 5=rheumatoid arthritis, 6=reactive arthritis) 7. What percentage of patients had rheumatoid arthritis as their primary diagnosis? 8. What percentage of patients had irritable bowel syndrome as their primary diagnosis? 9. What is the 95% CI for age? 10. What percentage of patients had psoriatic arthritis as their primary diagnosis? 7. What percentage of patients had rheumatoid arthritis as their primary diagnosis? 8. What percentage of patients had irritable bowel syndrome as their primary diagnosis? 9. What is the 95% CI for age? 10. What percentage of patients had psoriatic arthritis as their primary diagnosis? TABLE 27-4 DEMOGRAPHIC VARIABLES OF VETERANS WITH RHEUMATOID ARTHRITIS ID Age Race Ethnicity Gender Tobacco Diagnosis Biologic 0.1 42 41 Black, not of 0.3 Hispanic Origin Inflaimab 1.5 86 Black, not of Etanercept Hispanic origin 49 Caucasian 35 Caucasian 3.0 59 Black, not of Hispanic Origin 10 4.0 37 Caucasian Etanercept
Explanation / Answer
7.) Percentage of patients had rheumatoid arthritis as their primary diagnosis = [no of patients had rheumatoid arthritis as their primary diagnosis*100 / total patients]
= 5*100/10 = 50%
8.) Similar to previous question,
percentage of patients had irritable bowel syndrome as their primary diagnosis = 3*100 / 10 = 30%
9.) µage = 56.5; age = 19.2599
z-value for 95% CI = 1.96
CI = [µage ± z*age]
= [56.5 ± 1.96*19.2599]
= [18.75056, 94.24944]
10.) Similar to 7. and 8.
Percentage of patients had psoriatic arthritis as their primary diagnosis = 1*100/10 = 10%
Related Questions
Hire Me For All Your Tutoring Needs
Integrity-first tutoring: clear explanations, guidance, and feedback.
Drop an Email at
drjack9650@gmail.com
drjack9650@gmail.com
Navigate
Integrity-first tutoring: explanations and feedback only — we do not complete graded work. Learn more.